Separately, Barclays upgraded shares of Hvivo to an overweight rating in a report on Wednesday, September 19th.
HVO stock remained flat at $GBX 54.50 ($0.71) during midday trading on Thursday. 8,042 shares of the company traded hands, compared to its average volume of 49. Hvivo has a 1-year low of GBX 50 ($0.65) and a 1-year high of GBX 136.89 ($1.79).
In other news, insider Trevor Phillips acquired 23,500 shares of Hvivo stock in a transaction on Thursday, August 9th. The stock was acquired at an average cost of GBX 65 ($0.85) per share, with a total value of £15,275 ($19,959.49). Also, insider James Winschel acquired 6,420 shares of Hvivo stock in a transaction on Monday, October 8th. The stock was purchased at an average cost of GBX 62 ($0.81) per share, with a total value of £3,980.40 ($5,201.10).
Hvivo Company Profile
hVIVO plc, a specialty biopharma company, provides medical and scientific research services in the United Kingdom, the United States, and Europe. The company is developing a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases, including influenza virus, respiratory syncytial virus, asthma exacerbation, and human rhinovirus.
Read More: Diversification
Receive News & Ratings for Hvivo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo and related companies with MarketBeat.com's FREE daily email newsletter.